Core Viewpoint - Rosen Law Firm is reminding purchasers of Acadia Healthcare Company, Inc. securities of the upcoming lead plaintiff deadline in a securities class action lawsuit, emphasizing the potential for compensation without out-of-pocket costs for eligible investors [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between February 28, 2020, and October 18, 2024, with a lead plaintiff deadline set for December 16, 2024 [1]. - Investors who purchased Acadia Healthcare securities during the specified period may be entitled to compensation through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information via the provided link or contact the firm directly [3][6]. Group 2: Allegations Against Acadia Healthcare - The lawsuit alleges that Acadia Healthcare made materially false and misleading statements regarding its business practices, including holding vulnerable individuals against their will and subjecting patients to abuse [5]. - It is claimed that Acadia Healthcare deceived insurance providers into covering unnecessary stays in its facilities, leading to significant misrepresentation of its business operations and prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - A securities class action lawsuit has been filed against Acadia Healthcare Company, Inc. for allegedly making false and misleading statements regarding its business practices and patient care during the Class Period from February 28, 2020, to October 30, 2024 [1][3]. Group 1: Allegations Against Acadia Healthcare - The lawsuit claims that Acadia Healthcare admitted patients against their will and extended their stay beyond medical necessity to deceive payors into continuing payments for care [3]. - It is alleged that the company would not release patients until their insurance coverage was exhausted [3]. - Acadia Healthcare reportedly pressured emergency rooms to send patients to its facilities and filed frivolous legal petitions to delay patient releases [3]. - The company is accused of using misleading terminology in patient records to create a false impression of patients' mental states [3]. - The practices of Acadia Healthcare are said to have led to government investigations and negative media scrutiny, impacting its referral relationships [3]. - As a result of these issues, Acadia Healthcare experienced slower same-store patient volumes and was forced to lower its full-year 2024 outlook [3]. - The positive statements made by the defendants regarding the company's business and prospects are claimed to be materially false and misleading [3]. Group 2: Legal Process and Representation - Investors in Acadia Healthcare have until December 16, 2024, to seek appointment as lead plaintiff representatives in the class action [4]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [4]. - The lead plaintiff has the authority to select counsel to represent the class, and participation as a lead plaintiff does not affect the ability to share in any recovery [4].

Core Viewpoint - A lawsuit has been filed against Acadia Healthcare Company, Inc. and certain senior executives, alleging misrepresentation of financial results related to insurance fraud and improper patient detainment practices [1][2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until December 16, 2024, to request to lead the case [2]. Group 2: Allegations Against Acadia - Acadia is one of the largest for-profit psychiatric hospital chains in the U.S., and the complaint alleges that the company misrepresented its financial results due to insurance fraud and holding patients against their will when not medically necessary [3]. - A New York Times investigation highlighted that Acadia's success was partly due to luring patients and detaining them unnecessarily, leading to a stock price drop of $3.72 per share (4.5%) on September 3, 2024 [4]. Group 3: Regulatory Scrutiny - On September 27, 2024, Acadia disclosed receiving requests for information from the U.S. Attorney's Office and a grand jury subpoena, resulting in a 16% decline in stock price from $75.66 to $63.28 per share [5]. - An October 18, 2024, New York Times article reported that the Veterans Affairs Department is investigating Acadia for potential insurance fraud, causing a further 12% decline in stock price from $59.32 to $52.03 per share [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Acadia Healthcare Company, alleging that the company made materially false and misleading statements regarding its business practices and financial performance during the class period from February 8, 2020, to October 30, 2024 [1][2]. Company Overview - Acadia Healthcare is described as the leading publicly traded pure-play provider of behavioral healthcare services in the United States, focusing on high-quality, cost-effective services while aiming to grow its business and profitability [4]. - The majority of Acadia's revenue is derived from acute inpatient psychiatric facilities, with significant payments coming from Medicaid programs [4]. Allegations in the Class Action - The lawsuit claims that Acadia engaged in deceptive practices, including holding patients against their will and beyond medically necessary durations to secure continued payments from payors [5]. - It is alleged that Acadia pressured emergency rooms to admit patients and delayed patient releases through legal maneuvers, creating a false impression of patients' mental states [5]. - The complaint asserts that these practices would lead to government investigations and negatively impact Acadia's relationships with referral sources, ultimately affecting patient volumes and financial outlook [5]. Impact of Media Reports - The truth about Acadia's practices began to surface following a New York Times article published on September 1, 2024, which reported on the company's alleged wrongful detainment of patients, resulting in a stock price drop of over 4.5% [6]. - Subsequent articles revealed a $20 million settlement with the U.S. Department of Justice and investigations into Acadia's practices, leading to further declines in stock price, including a drop of over 16% following the disclosure of a grand jury subpoena [7][8]. - On October 18, 2024, another article indicated that the Veterans Affairs Department was investigating Acadia for potential insurance fraud, causing the stock to fall by more than 12% [10]. Financial Disclosure and Stock Performance - On October 30, 2024, Acadia announced a lowered full-year 2024 revenue outlook to between $3.15 billion and $3.165 billion, along with adjusted EBITDA guidance of $725 million to $735 million, attributing the decline to slower patient day growth [11]. - Following this announcement, Acadia's stock price fell by over 18%, reflecting the market's reaction to the negative news and revised financial outlook [11].

Core Viewpoint - A securities class action lawsuit has been filed against Acadia Healthcare Company, Inc. for allegedly making materially false and misleading statements regarding its business practices and patient treatment during the Class Period from February 28, 2020, to October 18, 2024 [1][3]. Group 1: Allegations Against Acadia Healthcare - The lawsuit claims that Acadia Healthcare's business model involved holding vulnerable individuals against their will in its facilities, even when not medically necessary [3]. - It is alleged that many patients in Acadia Healthcare facilities were subjected to abuse [3]. - The company is accused of deceiving insurance providers into covering costs for patients who did not require hospitalization [3]. - As a result of these practices, the statements made by Acadia Healthcare regarding its business operations and future prospects were deemed materially false and misleading [3]. Group 2: Legal Process and Investor Information - Investors in Acadia Healthcare have until December 16, 2024, to seek appointment as a lead plaintiff representative in the class action lawsuit [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case and who are representative of the class [4]. - Investors who have suffered significant losses are encouraged to contact Kessler Topaz Meltzer & Check, LLP for more information [5].

Core Points - Rosen Law Firm is reminding purchasers of Acadia Healthcare Company, Inc. securities of the December 16, 2024 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Acadia Healthcare securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Case Details - The lawsuit alleges that Acadia Healthcare made materially false and misleading statements regarding its business practices, including holding vulnerable individuals against their will and subjecting patients to abuse [5] - It is claimed that Acadia Healthcare deceived insurance providers into covering unnecessary stays in its facilities, leading to significant damages for investors when the truth was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [4] - The Rosen Law Firm has a history of successful settlements and has recovered hundreds of millions of dollars for investors [4]

Core Viewpoint - A lawsuit has been filed against Acadia Healthcare Company, Inc. and certain senior executives, alleging misrepresentation of financial results related to insurance fraud and improper patient detainment practices [1][2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until December 16, 2024, to request to lead the case [2]. Group 2: Allegations Against Acadia Healthcare - Acadia is one of the largest for-profit psychiatric hospital chains in the U.S., and the complaint alleges that the company misrepresented its financial results due to practices involving insurance fraud and holding patients against their will [3]. - A New York Times article highlighted that Acadia has been accused of luring patients and detaining them unnecessarily, which led to a stock price drop of $3.72 per share (4.5%) on September 3, 2024 [4]. - Following disclosures of investigations by the U.S. Attorney's Office and the SEC regarding patient admissions and billing practices, Acadia's stock fell by 16%, from $75.66 to $63.28 per share on September 27, 2024 [5]. - An investigation by the Veterans Affairs Department into potential insurance fraud by Acadia resulted in a further 12% decline in stock price, from $59.32 to $52.03 per share on October 18, 2024 [6]. Group 3: Legal Representation - Investors in Acadia Healthcare are encouraged to submit their information for potential legal representation, with no upfront costs as the firm operates on a contingency fee basis [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Acadia Healthcare Company, Inc. securities between February 28, 2020, and October 18, 2024, about the December 16, 2024, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Acadia Healthcare securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 16, 2024 [3]. Group 2: Case Allegations - The lawsuit alleges that Acadia Healthcare made materially false and misleading statements regarding its business practices, including holding vulnerable individuals against their will and subjecting patients to abuse [5]. - It is claimed that Acadia Healthcare deceived insurance providers into covering unnecessary stays in its facilities, leading to misleading statements about its operations and prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A lawsuit has been filed against Acadia Healthcare Company, Inc. for alleged misconduct during the Class Period from February 28, 2020, to October 18, 2024, impacting investors who purchased its securities [1][3]. Company Overview - Acadia Healthcare Company, Inc. is headquartered in Franklin, Tennessee, and provides behavioral healthcare services, including acute inpatient psychiatric facilities, residential recovery facilities, and comprehensive treatment centers [3]. Legal Issues - The lawsuit follows a New York Times article alleging that Acadia engaged in practices that unlawfully detained patients, leading to a significant drop in stock price by 4.5% on September 3, 2024 [4]. - On September 27, 2024, Acadia disclosed receiving requests for information from the U.S. Attorney's Office and a grand jury subpoena regarding its patient admissions and billing practices, resulting in a further decline of over 16% in stock price [5][6]. - An investigation by the Veterans Affairs Department into potential fraud against U.S. health insurance programs was reported on October 18, 2024, causing shares to fall by 12% [6][7].

Company Overview - Acadia Healthcare Company, Inc. (ACHC) is currently experiencing significant attention in the options market, particularly with the December 20, 2024 $90 Call option showing high implied volatility, indicating expectations of a substantial price movement [1] Analyst Sentiment - Acadia Healthcare holds a Zacks Rank of 5 (Strong Sell) within the Medical – Hospital industry, which is positioned in the top 32% of the Zacks Industry Rank [3] - Over the past 60 days, there have been no increases in earnings estimates for the current quarter, while five analysts have reduced their estimates, leading to a decrease in the Zacks Consensus Estimate from $0.85 to $0.74 per share [3] Options Market Dynamics - The high implied volatility surrounding Acadia Healthcare suggests that options traders anticipate a significant price movement, which could indicate an upcoming event that may lead to either a rally or a sell-off [2][4] - Options traders often seek to sell premium on options with high implied volatility, aiming to benefit from the decay of the option's value if the underlying stock does not move as much as expected by expiration [4]